Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer
Objective: To evaluate the perioperative as well as early oncological outcomes of patients undergoing robotic retroperitoneal lymph node dissection for treatment of testicular cancer. Methods: We conducted a prospective consecutive case series of patients undergoing robotic assisted retroperitoneal...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Asian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388222000546 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849698556645998592 |
|---|---|
| author | George McClintock Ahmed S. Goolam Don Perera Ryan Downey Scott Leslie Peter Grimison Henry Woo Peter Ferguson Nariman Ahmadi |
| author_facet | George McClintock Ahmed S. Goolam Don Perera Ryan Downey Scott Leslie Peter Grimison Henry Woo Peter Ferguson Nariman Ahmadi |
| author_sort | George McClintock |
| collection | DOAJ |
| description | Objective: To evaluate the perioperative as well as early oncological outcomes of patients undergoing robotic retroperitoneal lymph node dissection for treatment of testicular cancer. Methods: We conducted a prospective consecutive case series of patients undergoing robotic assisted retroperitoneal lymph node dissection for metastatic testicular cancer between May 2018 and July 2021 at our institution. Data were collected on patient and tumour characteristics, intraoperative and postoperative parameters, and functional and oncological outcomes. Descriptive statistics are presented. Results: Nineteen patients were identified; 18 (94.7%) completed the procedure robotically and one was converted to open surgery; 78.9% of patients had stage ≥IIB and 12 (63.2%) patients had undergone prior chemotherapy. The median operative time was 300 (interquartile range [IQR] 240–315) min. Median blood loss was 100 (IQR 50–175) mL. Median length of stay was 2 (range 1–11) days. All robotically completed patients commenced diet and passed flatus on Day 1 and were discharged by Day 3. The median lymph node yield was 40.5 (IQR 38–51) nodes. All patients undergoing nerve-sparing procedures recovered antegrade ejaculatory function. One patient had a Clavien-Dindo III complication (chylous ascites requiring drainage). At a median follow-up of 22.3 (IQR 16.3–24.9) months, one patient developed retroperitoneal recurrence, which was successfully treated with second-line chemotherapy; no other patients have had recurrences. Conclusion: Robotic retroperitoneal lymph node dissection is a safe and feasible alternative to open surgery in appropriately selected patients, offering low morbidity. Early oncological outcomes are promising. Larger cohorts and longer follow-ups are required to validate our institution's findings. |
| format | Article |
| id | doaj-art-9371fd9fd60b47918435b4f8418889db |
| institution | DOAJ |
| issn | 2214-3882 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Urology |
| spelling | doaj-art-9371fd9fd60b47918435b4f8418889db2025-08-20T03:18:53ZengElsevierAsian Journal of Urology2214-38822024-01-0111112112710.1016/j.ajur.2022.03.010Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancerGeorge McClintock0Ahmed S. Goolam1Don Perera2Ryan Downey3Scott Leslie4Peter Grimison5Henry Woo6Peter Ferguson7Nariman Ahmadi8Department of Urology, Chris O'Brien Lifehouse, Sydney, NSW, Australia; Corresponding author.Department of Urology, Chris O'Brien Lifehouse, Sydney, NSW, AustraliaDepartment of Anaesthesia, Chris O'Brien Lifehouse, Sydney, NSW, AustraliaDepartment of Anaesthesia, Chris O'Brien Lifehouse, Sydney, NSW, AustraliaDepartment of Urology, Chris O'Brien Lifehouse, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, 2006, AustraliaThe University of Sydney, Sydney, NSW, 2006, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, AustraliaDepartment of Urology, Chris O'Brien Lifehouse, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, 2006, AustraliaThe University of Sydney, Sydney, NSW, 2006, AustraliaDepartment of Urology, Chris O'Brien Lifehouse, Sydney, NSW, AustraliaObjective: To evaluate the perioperative as well as early oncological outcomes of patients undergoing robotic retroperitoneal lymph node dissection for treatment of testicular cancer. Methods: We conducted a prospective consecutive case series of patients undergoing robotic assisted retroperitoneal lymph node dissection for metastatic testicular cancer between May 2018 and July 2021 at our institution. Data were collected on patient and tumour characteristics, intraoperative and postoperative parameters, and functional and oncological outcomes. Descriptive statistics are presented. Results: Nineteen patients were identified; 18 (94.7%) completed the procedure robotically and one was converted to open surgery; 78.9% of patients had stage ≥IIB and 12 (63.2%) patients had undergone prior chemotherapy. The median operative time was 300 (interquartile range [IQR] 240–315) min. Median blood loss was 100 (IQR 50–175) mL. Median length of stay was 2 (range 1–11) days. All robotically completed patients commenced diet and passed flatus on Day 1 and were discharged by Day 3. The median lymph node yield was 40.5 (IQR 38–51) nodes. All patients undergoing nerve-sparing procedures recovered antegrade ejaculatory function. One patient had a Clavien-Dindo III complication (chylous ascites requiring drainage). At a median follow-up of 22.3 (IQR 16.3–24.9) months, one patient developed retroperitoneal recurrence, which was successfully treated with second-line chemotherapy; no other patients have had recurrences. Conclusion: Robotic retroperitoneal lymph node dissection is a safe and feasible alternative to open surgery in appropriately selected patients, offering low morbidity. Early oncological outcomes are promising. Larger cohorts and longer follow-ups are required to validate our institution's findings.http://www.sciencedirect.com/science/article/pii/S2214388222000546Retroperitoneal lymph node dissectionRobotic surgeryTesticular cancerRetroperitoneal node dissection |
| spellingShingle | George McClintock Ahmed S. Goolam Don Perera Ryan Downey Scott Leslie Peter Grimison Henry Woo Peter Ferguson Nariman Ahmadi Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer Asian Journal of Urology Retroperitoneal lymph node dissection Robotic surgery Testicular cancer Retroperitoneal node dissection |
| title | Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer |
| title_full | Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer |
| title_fullStr | Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer |
| title_full_unstemmed | Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer |
| title_short | Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer |
| title_sort | robotic assisted retroperitoneal lymph node dissection for stage ii testicular cancer |
| topic | Retroperitoneal lymph node dissection Robotic surgery Testicular cancer Retroperitoneal node dissection |
| url | http://www.sciencedirect.com/science/article/pii/S2214388222000546 |
| work_keys_str_mv | AT georgemcclintock roboticassistedretroperitoneallymphnodedissectionforstageiitesticularcancer AT ahmedsgoolam roboticassistedretroperitoneallymphnodedissectionforstageiitesticularcancer AT donperera roboticassistedretroperitoneallymphnodedissectionforstageiitesticularcancer AT ryandowney roboticassistedretroperitoneallymphnodedissectionforstageiitesticularcancer AT scottleslie roboticassistedretroperitoneallymphnodedissectionforstageiitesticularcancer AT petergrimison roboticassistedretroperitoneallymphnodedissectionforstageiitesticularcancer AT henrywoo roboticassistedretroperitoneallymphnodedissectionforstageiitesticularcancer AT peterferguson roboticassistedretroperitoneallymphnodedissectionforstageiitesticularcancer AT narimanahmadi roboticassistedretroperitoneallymphnodedissectionforstageiitesticularcancer |